BioXcel Therapeutics (BTAI) Change in Accured Expenses (2017 - 2026)

BioXcel Therapeutics' Change in Accured Expenses history runs 10 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 197.62% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $4.5 million, a 175.02% increase from a year earlier, with the FY2024 full-year figure at -$4.3 million, down 273.29% from the prior year.
• Change in Accured Expenses grew to $2.2 million in Q1 2026 per BTAI's latest filing, from -$45000.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $10.1 million in Q4 2022 and bottomed at -$4.7 million in Q1 2023.
• The 5-year median for Change in Accured Expenses is -$232000.0 (2022), against an average of $838437.5.
• Across the five-year window, Change in Accured Expenses soared 2458.33% in 2022 and tumbled 588.46% in 2023, its largest moves.
• Year by year, Change in Accured Expenses stood at $10.1 million in 2022, then sank by 86.74% to $1.3 million in 2023, then sank by 347.77% to -$3.3 million in 2024, then soared by 98.65% to -$45000.0 in 2025, then surged by 5022.22% to $2.2 million in 2026.
• Per Business Quant, the three latest BTAI Change in Accured Expenses figures stand at $2.2 million (Q1 2026), -$45000.0 (Q3 2025), and $2.3 million (Q2 2025).